Comparing docetaxel with gemcitabine as second-line chemotherapy in patients with advanced non-small cell lung cancer: A single institute randomized phase II study
Journal Title: Journal of Cancer Research & Therapy - Year 2015, Vol 3, Issue 1
Abstract
Background: Platinum-based doublet chemotherapy is the backbone of treatment in advanced non-small cell lung cancer (NSCLC) however second-line treatment options are controversial particularly in patients with borderline performance status (PS) of 2. The aim of this study was to compare efficacy and toxicity of weekly docetaxel versus gemcitabine in this clinical setting. Patients and methods: A total of 70 patients with advanced (stage IIIB, IV) NSCLC entered this single institute study. Cases of this study had experienced disease progression after the first-line platinum-based doublet chemotherapy, with PS 0- 2 in “Eastern Cooperative Oncology Group” scale. They were randomly assigned by stratified blocks to receive docetaxel 35 mg/m2 (Arm A, n=34) or gemcitabine 1000 mg/m2 (Arm B, n=36) days 1, 8 and 15, every three weeks, for up to six cycles. Primary end point was progression free survival (PFS) and secondary end points were objective response rate, disease control rate, median overall survival (OS) and toxicity. Dose modification was permitted upon clinician’s discretion for each individual patient. Results: Median of PFS was 2.02 months in arm A and 2.63 months in arm B (HR= 1.279; 95% CI: 0.710-2.304, P= 0.551). Although median OS for arm A was numerically greater (9.2 months) than arm B (8.3 months) it was statistically non-significant (HR= 1.384; 95% CI: 0.632 to 2.809, P= 0.59). Objective response was higher in Arm B than that in Arm A (P= 0.20) but disease control rates were statistically different in both arms (P= 0.034). Statistically significant differences in term of leukopenia was seen in arm B (P= 0.013). Conclusion: This study, with limited number of cases, indicates that in advanced NSCLC, weekly docetaxel and gemcitabine are reasonable second-line treatment options with statistically similar effectiveness in terms of PFS and median OS with manageable toxicities in patients with PS 0-2.
Authors and Affiliations
Khosravi A, Esfahani-Monfared Z, Karimi SH, Emami H, Khodadad K
Keywords
Related Articles
- EP ID EP544835
- DOI 10.14312/2052-4994.2015-1
- Views 58
- Downloads 0
Ecological model links proto-oncogene to high incidence of metastatic cancers in African-Americans
Cancers identified by the uncontrolled proliferation of the TRPV6 mRNA biomarker, kill African-Americans (AAs) at nearly twice the rate of Whites. Malignancies assigned to this class include: Metastatic prostate cancer,...
Malignant solitary fibrous tumor of the sacrum: A case report
The solitary fibrous tumor (SFT) is a rare ubiquitous mesenchymal neoplasm of fibroblastic type, which shows a prominent hemangiopericytoma-like branching vascular pattern. Approximately 40% of solitary fibrous tumors ar...
Contributions of stochastic events to biological evolution and cancer
Stochastic genetic and epigenetic events have been fundamental in contributing to the development of manifold life-forms, past and present. The development of malignant cell clones and the role of stochasticity as a driv...
Trastuzumab therapy in metastatic bladder carcinoma: The proof of concept
About 10% of metastatic urothelial carcinoma overexpress oncogenic HER2/neu receptor. Recent preliminary data suggest that patients with this particular molecular subset could benefit from trastuzumab therapy, which spec...
Clinicopathological study of gene rearrangement and immunohistochemical pattern of primary intracranial diffuse large B-cell lymphomas
We studied the clinicopathological and imaging characteristics of primary intracranial diffuse large B-cell lymphomas (PIC-DLBCL). Imaging, histopathological findings, and immunohistochemical staining characteristics wer...